Can Sjögren's syndrome affect the kidneys?

Renal Involvement in Sjögren's Syndrome

Yes, Sjögren's syndrome can affect the kidneys, occurring in approximately 9-30% of patients, with tubulointerstitial nephritis (TIN) being the most common manifestation, followed less frequently by glomerular disease.

Prevalence and Clinical Significance

Renal involvement in primary Sjögren's syndrome (pSS) is an under-recognized but clinically important extraglandular manifestation:

• Prevalence ranges from 9-30% across different cohorts, with subclinical disease being more common than overt manifestations 1, 2, 3
• Severe renal disease requiring kidney biopsy occurs in approximately 2% of patients 2
• Renal involvement can occur at any time during the disease course, and may even precede the onset of sicca symptoms in some patients 4

Types of Renal Manifestations

Tubulointerstitial Nephritis (Most Common)

TIN is the predominant form of kidney involvement in Sjögren's syndrome, characterized by lymphoplasmacytic infiltration of the renal interstitium similar to the infiltration seen in salivary glands 5, 4:

• Renal tubular acidosis (RTA) is the most frequent clinical presentation, particularly distal RTA (type 1), occurring in up to 50% of patients with renal involvement 3
• Patients with RTA commonly present with hypokalemic paralysis and are typically younger with fewer articular and sicca symptoms 3
• Other tubular dysfunction patterns include: nephrogenic diabetes insipidus, Gitelman-like syndrome, and Fanconi syndrome 5
• Electrolyte disturbances such as hypokalemia (7% of patients) are common 2, 4

Glomerular Disease (Less Common)

Glomerular involvement occurs less frequently but carries significant clinical implications 5, 4:

• Membranoproliferative glomerulonephritis is the most common glomerular pattern, often secondary to cryoglobulinemia 5
• IgA nephropathy has been documented on renal biopsy 3
• Nephrotic syndrome can occur, though it is rare 4

Predictive Factors and Associated Features

Several clinical and laboratory features predict the development of renal involvement 1, 2:

• Fatigue (OR 2.83) and the interaction between polyarthritis and vasculitis (OR 9.17) are independent predictors 1
• Older age (OR 1.03), higher ESSDAI scores (OR 1.1), anti-La/SSB positivity (OR 6.65), and non-vasculitic cutaneous involvement (OR 5.47) are independently associated with renal complications 2
• Additional predictive markers include: ANA positivity, anti-Ro52, lymphopenia, and thrombocytopenia 1
• Patients with renal involvement have more severe systemic disease, higher rates of multiorgan involvement, and increased frequency of lymphoma 2

Prognosis and Long-term Outcomes

While renal prognosis is generally favorable, significant morbidity can occur 2, 5:

• Chronic kidney disease develops in approximately 59% of patients with overt renal disease, though progression to end-stage renal disease requiring dialysis is rare (occurring in only 1 patient in one cohort) 2
• Patients with nephritis demonstrate worse event-free survival (death or CKD), with 89.1% event-free survival at 5 years 1
• Baseline hematuria, leukocyturia, 24-hour urinary protein, and thrombocytopenia are independent predictors of rising creatinine on follow-up 1
• Subclinical RTA may progress to complete RTA over time 3

Screening Recommendations

Appropriate screening must be performed at least annually in patients with systemic Sjögren's syndrome to facilitate early detection of renal complications 5:

• Baseline evaluation should include: serum electrolytes, creatinine, venous pH and bicarbonate, urinalysis, 24-hour urine collection for protein and creatinine clearance, and morning urine osmolality and pH 3, 4
• Water deprivation testing should be performed in patients with low morning urine osmolality to detect concentrating defects 4
• Oral ammonium chloride loading test should be performed in patients with persistently elevated urine pH (>5.5) to diagnose RTA 4
• Renal biopsy should be considered in all patients with clinically significant renal involvement, particularly those with proteinuria, declining renal function, or unexplained urinary abnormalities 3

Treatment Approach

Treatment depends on the type and severity of renal involvement 2, 3:

• RTA requires alkali replacement therapy to correct acidosis and prevent complications 3
• Moderate-to-severe TIN should be treated with oral corticosteroids (typically prednisolone), though only marginal improvement in eGFR may be observed 3
• Glomerular disease management follows standard protocols for the specific glomerular pathology identified on biopsy 5

Common Pitfalls

Key clinical considerations to avoid missed or delayed diagnosis:

• Renal involvement is often subclinical, requiring active screening rather than waiting for symptoms 3, 4
• Younger patients with hypokalemic paralysis and minimal sicca symptoms should be evaluated for Sjögren's-related RTA 3
• Renal manifestations may precede the diagnosis of Sjögren's syndrome, so unexplained TIN or RTA should prompt evaluation for underlying autoimmune disease 4
• Despite generally favorable prognosis, the risk of chronic kidney disease remains high, necessitating long-term monitoring 5